Pancreatic Ductal Adenocarcinoma clinical trials

Explore recruiting pancreatic ductal adenocarcinoma clinical trials.

Recruiting pancreatic ductal adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Ductal Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

Spain, Italy, Netherlands, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC

Germany, Sweden, Finland, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Standard versus Prolonged Neoadjuvant (Conversion) Chemotherapy to prolong survival of patients with Borderline and Locally Advanced Pancreatic Cancer: a phase III randomized controlled trial

Sweden, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy

Germany, Spain, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma

Belgium, France, Germany, Sweden, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Pancreatic Ductal Adenocarcinoma trials by city

Pancreatic Ductal Adenocarcinoma in Toronto Pancreatic Ductal Adenocarcinoma in Vancouver Pancreatic Ductal Adenocarcinoma in Montreal Pancreatic Ductal Adenocarcinoma in Calgary Pancreatic Ductal Adenocarcinoma in Edmonton Pancreatic Ductal Adenocarcinoma in Ottawa Pancreatic Ductal Adenocarcinoma in Winnipeg Pancreatic Ductal Adenocarcinoma in Quebec City Pancreatic Ductal Adenocarcinoma in Hamilton Pancreatic Ductal Adenocarcinoma in Kitchener Pancreatic Ductal Adenocarcinoma in London Pancreatic Ductal Adenocarcinoma in Halifax Pancreatic Ductal Adenocarcinoma in New York Pancreatic Ductal Adenocarcinoma in Los Angeles Pancreatic Ductal Adenocarcinoma in Chicago Pancreatic Ductal Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease